Clinical characteristics of NMZL patient series
| Case no. . | Age, y/sex . | Clinical stage . | HCV . | IGHV gene . | ID, % homology . | Treatment . | Outcome (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | 60/F | III | Negative | VH3-33 | 98.2 | CHT | CR (120) |
| 2 | 80/M | II | ND | VH4-39 | 94 | RT | AWD (64) |
| 3 | 74/F | I | ND | VH3-72 | 93 | ND | AWD (30) |
| 4 | 76/F | III | ND | NR | — | CHT | CR (24) |
| 5 | 73/F | III | Negative | NR | — | CHT | DOD (18) |
| 6 | 62/F | ND | ND | NR | — | ND | ND |
| 7 | 65/F | ND | ND | VH4-34/VH3-7 | 95.9/89.6 | ND | ND |
| 8 | 82/F | III | Negative | VH4-39 | 92.3 | CHT | DXT (54) |
| 9 | 71/M | IV | Positive | VH3-74 | 97.3 | CHT | AWD (19) |
| 10 | 76/M | I | ND | VH3-21 | 93.8 | ND | ND |
| 11 | 55/F | IV | Positive | NR | — | CHT | AWD (34) |
| 12 | 69/F | III | Negative | NR | — | ND | CR (25) |
| 13 | 62/M | I | ND | NR | — | RT | CR (46) |
| 14 | 80/M | IV | ND | VH3-23/VH4b | 89.3/91.1 | CHT | DXT (13) |
| 15 | 53/M | IV | ND | VH3-11 | 89.7 | CHT | DOD (7) |
| Case no. . | Age, y/sex . | Clinical stage . | HCV . | IGHV gene . | ID, % homology . | Treatment . | Outcome (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | 60/F | III | Negative | VH3-33 | 98.2 | CHT | CR (120) |
| 2 | 80/M | II | ND | VH4-39 | 94 | RT | AWD (64) |
| 3 | 74/F | I | ND | VH3-72 | 93 | ND | AWD (30) |
| 4 | 76/F | III | ND | NR | — | CHT | CR (24) |
| 5 | 73/F | III | Negative | NR | — | CHT | DOD (18) |
| 6 | 62/F | ND | ND | NR | — | ND | ND |
| 7 | 65/F | ND | ND | VH4-34/VH3-7 | 95.9/89.6 | ND | ND |
| 8 | 82/F | III | Negative | VH4-39 | 92.3 | CHT | DXT (54) |
| 9 | 71/M | IV | Positive | VH3-74 | 97.3 | CHT | AWD (19) |
| 10 | 76/M | I | ND | VH3-21 | 93.8 | ND | ND |
| 11 | 55/F | IV | Positive | NR | — | CHT | AWD (34) |
| 12 | 69/F | III | Negative | NR | — | ND | CR (25) |
| 13 | 62/M | I | ND | NR | — | RT | CR (46) |
| 14 | 80/M | IV | ND | VH3-23/VH4b | 89.3/91.1 | CHT | DXT (13) |
| 15 | 53/M | IV | ND | VH3-11 | 89.7 | CHT | DOD (7) |
NMZL patients had a median age of 68.5 y (range, 53-82 y); 64% of them were women.
ID indicates identity frequency; CHT, chemotherapy; CR, complete remission; ND, not determined; RT, radiotherapy; AWD, alive with disease; NR, no rearrangement; —, not applicable; DOD, dead of disease; and DXT, dead, nonlymphoma-related.